Objectives This paper examines the differential impact of responsive parenting and nutrition interventions on early child ...

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...

A recent study revealed that regular physical activity, particularly walking, can minimise fatigue in people with colon ...

GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational ...

Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.

Topline data were announced from the phase 3 INDIGO trial evaluating obexelimab in adults with immunoglobulin G4-related disease.

The somewhat surprising finding came from a study of the lifespan and diets of more than 5,200 adults aged 80 and over.

Although the vast majority of physicians using an artificial intelligence (AI) scribe perceived a reduction in documentation time, those with the most actual time savings had higher relative baseline ...

As for the air quality impact to Connecticut over the past year, it's still too early to conclude if New York's congestion ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.